Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting
Author:
Open Access
Abstract
Ovarian cancer is the fifth leading cause of cancer deaths in women and is regarded as one of the most difficult cancers to treat. Currently, studies are being conducted to develop therapeutic agents for effective treatment of ovarian cancer. In this review, we explain the properties of the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) and how the signaling pathway of HGF/c-MET is activated in different cancers and involved in tumorigenesis and metastasis of ovarian cancer. We present the findings of clinical studies using small chemicals or antibodies targeting HGF/c-MET signaling in various cancer types, particularly in ovarian cancer. We also discuss that HGF/c-MET-targeted therapy, when combined with chemo drugs, could be an effective strategy for ovarian cancer therapeutics.Keywords
Funding Information
- the Korea government (MSIT) (No. 2020R1F1A1065142)
This publication has 110 references indexed in Scilit:
- Clinical use of crizotinib for the treatment of non-small cell lung cancerBiologics: Targets and Therapy, 2013
- Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastomaProceedings of the National Academy of Sciences, 2011
- Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progressionCancer and Metastasis Reviews, 2011
- Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer MetastasisClinical Cancer Research, 2011
- Early Clinical Development of ARQ 197, a Selective, Non–ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced CancersThe Oncologist, 2011
- Recent progress in the diagnosis and treatment of ovarian cancerCA: A Cancer Journal for Clinicians, 2011
- Review: Practical considerations in ovarian cancer chemotherapyTherapeutic Advances in Medical Oncology, 2010
- Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid TumorsClinical Cancer Research, 2010
- A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of MetJournal of Biological Chemistry, 2008
- Scatter factor is a fibroblast-derived modulator of epithelial cell mobilityNature, 1987